Aviragen Therapeutics, Inc. News (NASDAQ:AVIR)

DateTimeSource
Headline
11/09/20164:01PMGLOBEAviragen Therapeutics to Present at Stifel 2016 Healthcare Conference
ATLANTA, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that Aviragen’s CFO & Executive Vice President Mark Colonnese will present a corporate overview at the Stifel 2016 Healthcare Conference... More...>>
11/03/20164:01PMGLOBEAviragen Therapeutics Reports First Quarter Fiscal Year 2017 Financial Results
ATLANTA, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three month period ended September 30, 2016, which is the first quarter of the Company's 2017 fiscal year, and also provided an update on recent corporate developments. “Throughout the... More...>>
10/27/20164:39PMGLOBEAviragen Therapeutics to Host Conference Call to Report First Quarter Fiscal Year 2017 Financial Results on November 3, 2016
ATLANTA, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, November 3, 2016 at 4:30 p.m. ET to review the Company’s financial results for the... More...>>
10/10/20169:00AMGLOBEAviragen Therapeutics to Host KOL Meeting on HRV Infections on October 13, 2016 in New York
ATLANTA, Oct. 10, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, announced today that it will host a Key Opinion Leader (KOL) breakfast focused on the growing burden of human rhinovirus (HRV) infections in at-risk patient... More...>>
09/14/20164:01PMGLOBEAviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2016 Financial Results
ATLANTA, Sept. 14, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the fourth quarter and 2016 fiscal year ended June 30, 2016, and also provided an update on recent corporate and clinical developments. “Over the last twelve months we have made significant... More...>>
09/13/20167:00PMGLOBEAviragen Therapeutics Announces Rescheduled Date and Time of Fourth Quarter and Fiscal Year 2016 Financial Results on Septemb...
ATLANTA, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Wednesday, September 14, 2016 at 4:30 p.m. ET to review... More...>>
09/07/20169:00AMGLOBEAviragen Therapeutics to Present at Upcoming Investor Conferences
ATLANTA, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that Aviragen's CEO & President Joseph Patti, PhD will present a corporate overview at the... More...>>
09/06/20166:30PMGLOBEAviragen Therapeutics Announces Inducement Grant for New Employees
ATLANTA, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that the Company has granted two new hires options to purchase an aggregate of 125,000 shares of the... More...>>
09/06/20165:34PMGLOBEAviragen Therapeutics Announces Schedule Change for Fourth Quarter and Fiscal Year End 2016 Financial Results Conference Call...
ATLANTA, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that it is delaying the time of its fourth quarter and fiscal year end 2016 earnings conference... More...>>
09/01/20169:00AMGLOBEAviragen Therapeutics to Host Conference Call to Report Fourth Quarter and Fiscal Year 2016 Financial Results on September 8,...
ATLANTA, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, September 8, 2016 at 4:30 p.m. ET to review... More...>>
07/12/20167:00AMGLOBEAviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial
ATLANTA, July 12, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced it is resuming enrollment in its Phase 2a challenge study of BTA585, an oral fusion inhibitor in development... More...>>
07/05/20167:00AMGLOBEAviragen Therapeutics and Georgia State University Research Foundation Enter Exclusive License and Sponsored Research Agreeme...
ATLANTA, July 05, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that it has entered into an exclusive, worldwide license and sponsored research agreement with Georgia... More...>>
07/01/20164:01PMGLOBEAviragen Therapeutics Announces Inducement Grant for New Employee
ATLANTA, July 01, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that the compensation committee of the Company’s Board of Directors granted to Jonas Niaura, Vice... More...>>
06/28/20169:00AMGLOBEAviragen Therapeutics Announces the Appointment of Jonas Niaura as Vice President, Corporate Development and Strategy
ATLANTA, June 28, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced the appointment of Jonas Niaura as Vice President, Corporate Development and Strategy. “Jonas brings to Aviragen considerable business development... More...>>
05/26/20164:30PMGLOBEAviragen Therapeutics Provides Update on Phase 2a Trial of BTA585 for the Treatment of RSV Infections
ATLANTA, May 26, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that it has voluntarily decided to delay further enrollment in the Phase 2a trial of BTA585 for the treatment... More...>>
05/05/20164:01PMGLOBEAviragen Therapeutics Reports Third Quarter Fiscal Year 2016 Financial Results
ATLANTA, May 05, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.) today announced its financial results for the three month period ended March 31, 2016, which is the third quarter of the Company's 2016 fiscal year, and also provided an update on recent corporate... More...>>
04/28/20164:01PMGLOBEAviragen Therapeutics to Host Conference Call to Report Third Quarter Fiscal Year 2016 Financial Results on May 5, 2016
ATLANTA, April 28, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.) a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, May 5, 2016 at 4:30 p.m. ET to review the Company’s... More...>>
04/28/201611:46AMGLOBEAviragen Therapeutics Completes Royalty Deal With HealthCare Royalty Partners for Proceeds of $20 Million
ATLANTA, April 25, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.) a pharmaceutical company that is developing the next generation of antivirals, today announced that it has signed a definitive agreement to receive a cash payment of $20 million from HealthCare Royalty... More...>>
04/14/20164:01PMGLOBEAviragen Therapeutics to Participate in FBR & Co. Healthcare Series Focused on Infectious Diseases
ATLANTA, April 14, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc., (NASDAQ:AVIR), formerly Biota Pharmaceuticals, Inc., today announced that Joseph Patti, PhD, President & CEO of Aviragen Therapeutics, will participate in a panel discussion titled, “Notable Emerging Anti-Viral Agents” as part of the FBR &... More...>>
04/12/20167:00AMGLOBEBiota Pharmaceuticals, Inc. Announces Name Change to Aviragen Therapeutics, Inc. (NASDAQ: AVIR)
ATLANTA, April 12, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced that the Company has changed its name to Aviragen Therapeutics, Inc., (“Aviragen Therapeutics”), a pharmaceutical company focused on the development of the next generation of direct-acting antivirals that address infections... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V:us D:20161210 01:09:06